NDAQ vs CME โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NDAQ Captures Institutional Edge (3โ1 Pillars ยท 3โ7 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nasdaq, Inc. Common Stock (NDAQ) driven by superior Valuation, Momentum & Technical, Options & Structure while CME counters with relative strength in Growth & Margin. Fundamentally, NDAQ trades at 22.9x Forward P/E with 49.0% operating margin (+12.6% YoY revenue) versus CME at 24.1x Forward P/E and 66.2% operating margin (+13.0% YoY). In options structure, NDAQ sits in CONSOLIDATION (10th %ile IV; Dealer Gamma Walls on Pro) against CME sits in CONSOLIDATION (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NDAQ Revenue | CME Revenue | NDAQ Op. Margin | CME Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $4.28B | $4.31B | 24.0% | 60.5% | CME |
| FY2019 | $4.26B | $4.87B | 23.9% | 53.2% | CME |
| FY2020 | $5.62B | $4.88B | 21.9% | 54.0% | CME |
| FY2021 | $5.89B | $4.69B | 24.5% | 56.4% | CME |
| FY2022 | $6.23B | $5.02B | 25.1% | 60.1% | CME |
| FY2023 | $6.06B | $5.58B | 26.0% | 61.6% | CME |
| FY2024 | $7.40B | $6.13B | 24.3% | 64.1% | CME |
| FY2025 | $8.26B | $6.52B | 28.2% | 64.9% | CME |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NDAQ | CME | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $60.2B | $113.8B | Larger Scale | CME |
| Trailing P/E Ratio Valuation | 29.6x | 26.1x | Lower Multiple | CME |
| Forward P/E Ratio Valuation | 22.9x | 24.1x | Lower Multiple | NDAQ |
| Revenue Growth (YoY) Growth | +12.6% | +13.0% | Higher Growth | CME |
| Operating Margin (TTM) Profitability | 49.0% | 66.2% | Higher Margin | CME |
| Net Profit Margin Profitability | 36.1% | 63.5% | Higher Margin | CME |
| Return on Equity (ROE) Capital Efficiency | 17.3% | 16.1% | Higher ROE | NDAQ |
| 52-Week Range Position Momentum | 82% ($77โ$111) | 84% ($218โ$329) | Stronger Trend | CME |
| Beta / 30D Volatility Risk Regime | 0.43ฮฒ ยท 32% Vol | -0.32ฮฒ ยท 26% Vol | Lower Realized Risk | CME |
| Unified Institutional Score Composite Signal | 45.2 / 100 (HOLD) | 38.6 / 100 (SELL) | Higher Composite | NDAQ |